Top

Published in:

01-02-2010 | Original Article

Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP

Authors: Yee Soo Chae, Jong Gwang Kim, Sang Kyun Sohn, Joon Ho Moon, Shi Nae Kim, Su Jeong Lee, Tae-In Park, Myung-Hoon Lee

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2010

Abstract

Purpose

Diffuse large B cell lymphoma (DLBCL) is a heterogenous disease entity due to diverse clinical outcomes to treatment. Most anticancer agents, regardless of their distinct mechanisms of action, ultimately kill cancer cells by inducing apoptosis. Accordingly, the present study analyzed the impact of polymorphisms of apoptosis-related genes on outcome in DLBCL patient treated with R-CHOP.

Patients and methods

Ninety patients with DLBCL treated with R-CHOP were enrolled in the present study. The genomic DNA was extracted from paraffin-embedded tissue and 22 polymorphisms of 18 apoptosis-related genes were assessed using a polymerase chain reaction–restriction fragment length polymorphism assay.

Results

All the evaluable patients were responsive to R-CHOP. The multivariate analysis showed that the AA genotype of lymphotoxin alpha (LTA) C804A (rs1041981) and GG genotype of RIPK1 G83A (rs2272990) were significantly correlated with a worse time to progression (TTP) compared with the combined C/A and C/C genotype and the combined G/A and A/A genotype (hazard ratio [HR] = 7.92; 95% confidence interval [CI] = 1.42–44.18; P = 0.018 and HR = 20.02; 95% CI = 1.59–251.52; P value = 0.018, respectively), whereas no association was observed between the other polymorphisms and TTP.

Conclusion

The polymorphisms of LTA (rs1041981) and RIPK1 (rs2272990) may correlate with TTP in patients with DLBCL treated with R-CHOP.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B cell lymphoma. N Engl J Med 346:235–242CrossRefPubMed

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:4117–4126CrossRefPubMed

Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391CrossRefPubMed

Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B cell lymphoma. Biochem Soc Trans 25:705–708PubMed

Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443–446CrossRefPubMed

Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445PubMed

Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M (1997) Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 349:849CrossRefPubMed

Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis: its significance in cancer and cancer therapy. Cancer 73:2013–2026CrossRefPubMed

Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092–1100PubMed

10.

Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365CrossRefPubMed

11.

Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Chanock SJ, Inskip PD (2007) Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev 16:1655–1661CrossRefPubMed

12.

Kim JG, Sohn SK, Chae YS, Cho YY, Bae HI, Yan G, Park JY, Lee MH, Chung HY, Yu W (2007) Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 18:1030–1036CrossRefPubMed

13.

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas NCI Sponsored International Working Group. J Clin Oncol 17:1244PubMed

14.

Schwartz PS, Waxman DJ (2001) Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 60:1268–1279PubMed

15.

Gamen S, Anel A, Perez-Galan P, Lasierra P, Johnson D, Pineiro A, Naval J (2000) Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res 258:223–235CrossRefPubMed

16.

Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S (2000) Distinct pathways for stimulation of cytochrome c release by etoposide. J Biol Chem 275:32438–32443CrossRefPubMed

17.

Zhou X, Hu W, Qin X (2008) The role of complement in the mechanism of action of rituximab for B cell lymphoma: implications for therapy. Oncologist 13:954–966CrossRefPubMed

18.

Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153–164CrossRefPubMed

19.

Kitada S, Pedersen IM, Schimmer AD, Reed JC (2002) Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21:3459–3474CrossRefPubMed

20.

Zodelava M, Datikashvili-David I (2005) Prognostic significance of apoptosis-related CD95 antigen expression in patients with non-Hodgkin’s lymphoma. Georgian Med News 3:7–9

21.

Yasuda H, Sugimoto K, Imai H, Isobe Y, Sasaki M, Kojima Y, Nakamura S, Oshimi K (2009) Expression levels of apoptosis-related proteins and Ki-67 in nasal NK/T cell lymphoma. Eur J Haematol 82:39–45CrossRefPubMed

22.

ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W, Hack CE, Ossenkoppele GJ, Oudejans JJ (2002) Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 99:4540–4546CrossRefPubMed

23.

Sohn SK, Jung JT, Kim DH, Kim JG, Kwak EK, Park T, Shin DG, Sohn KR, Lee KB (2003) Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B cell lymphoma. Am J Hematol 73:101–107CrossRefPubMed

24.

Jost PJ, Ruland J (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109:2700–2707PubMed

25.

Karin M, Lin A (2002) NF-kB at the crossroads of life and death. Nat Immunol 3:221–227CrossRefPubMed

26.

Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, Coiffier B, Salles G (1998) Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin’s lymphoma outcome. Blood 91:3574–3581PubMed

27.

Seidemann K, Zimmermann M, Book M, Meyer U, Burkhardt B, Welte K, Reiter A, Stanulla M (2005) Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin’s lymphoma: results from Berlin–Frankfurt–Munster Trial NHL-BFM 95. J Clin Oncol 23:8414–8421CrossRefPubMed

28.

Takei K, Ikeda S, Arai T, Tanaka N, Muramatsu M, Sawabe M (2008) Lymphotoxin-alpha polymorphisms and presence of cancer in 1, 536 consecutive autopsy cases. BMC Cancer 8:235CrossRefPubMed

29.

Niwa Y, Ito H, Matsuo K, Hirose K, Ito N, Mizuno M, Hamajima N, Tajima K, Nakanishi T (2007) Lymphotoxin-alpha polymorphisms and the risk of endometrial cancer in Japanese subjects. Gynecol Oncol 104:586–590CrossRefPubMed

30.

Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Sato H, Hori M, Nakamura Y, Tanaka T (2002) Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32:650–654CrossRefPubMed

31.

Messer G, Spengler U, Jung MC, Honold G, Blomer K, Pape GR, Riethmuller G, Weiss EH (1991) Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 173:209–219CrossRefPubMed

32.

Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV (1996) TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4:387–396CrossRefPubMed

33.

Jagiello P, Gencik M, Arning L, Wieczorek S, Kunstmann E, Csernok E, Gross WL, Epplen JT (2004) New genomic region for Wegener’s granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet 114:468–477CrossRefPubMed

Title: Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP
Authors: Yee Soo Chae
Jong Gwang Kim
Sang Kyun Sohn
Joon Ho Moon
Shi Nae Kim
Su Jeong Lee
Tae-In Park
Myung-Hoon Lee
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2010
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-009-1066-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2010

MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer

Pharmacokinetic interaction between tamoxifen and ondansetron in rats: non-competitive (hepatic) and competitive (intestinal) inhibition of tamoxifen metabolism by ondansetron via CYP2D subfamily and 3A1/2

Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer

A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer

A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer

Pharmacokinetics and tissue distribution of PGG–paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer